Crossmark

A new patient‐derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α‐dystroglycan

Crossref DOI link: https://doi.org/10.15252/embr.201947967

Published Online: 2019-09-30

Published Print: 2019-11-05

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Kim, Jihee

Lana, Beatrice

Torelli, Silvia

Ryan, David

Catapano, Francesco

Ala, Pierpaolo

Luft, Christin

Stevens, Elizabeth

Konstantinidis, Evangelos

Louzada, Sandra

Fu, Beiyuan

Paredes‐Redondo, Amaia

Chan, AW Edith

Yang, Fengtang

Stemple, Derek L https://orcid.org/0000-0002-8296-9928
Liu, Pentao

Ketteler, Robin https://orcid.org/0000-0002-2786-7291
Selwood, David L https://orcid.org/0000-0002-6817-5064
Muntoni, Francesco

Lin, Yung‐Yao https://orcid.org/0000-0002-0435-7694
Funding

Funding for this research was provided by:

Royal Society (RG130417)

Seventh Framework Programme (115582, 2012‐305121)

Medical Research Council (MC_U12266B, 92‐963)

Wellcome Trust (098051)
License Information

Version of Record valid from 2019-09-30
More Information

Publication History

Received: 2019-03-04

Accepted: 2019-08-29

Published: 2019-09-30